In 2011, Evotec, Harvard and the Howard Hughes Medical Institute collaborated to analyse and characterise drug candidates identified by scientists at the Harvard University laboratory of Douglas Melton.
US-based healthcare products company Johnson & Johnson’s Janssen Research & Development is licensing a portfolio of biologic research programs for diabetics by Germany-based healthcare company Evotec and Harvard University.
The technology focuses on the regeneration of insulin-producing beta cells.
In 2011, Evotec, Harvard and the Howard Hughes Medical Institute collaborated to analyse and characterise drug candidates identified by scientists at the Harvard University laboratory of Douglas Melton.
Peter DiBattiste, global therapeutic head of cardiovascular and metabolism at Janssen Research &…
